Exclusion criteria were diabetes, autoimmune diseases and tuberculosis. Biological samples were collected before RR treatment with prednisone. Clinical data of these patients are described in Table 1. Peripheral blood mononuclear cells (PBMCs) were isolated under endotoxin-free conditions from heparinized venous blood by Ficoll–Hypaque

(Pharmacia Fine Chemicals, Piscataway, NJ) density centrifugation. Whole irradiated ML (10 μg/ml) (provided by Dr Brennan; Microbiology LDK378 price Department, Colorado State University, Fort Collins, CO) and two different specific peptides from ML, namely, p38 (TRLLTVVVKQRSKAF)[22] and p69 (RLDGTTLEV)[22] at 10 μg/ml, (generously donated by Dr Geraldo Pereira; FIOCRUZ-RJ), were used for in vitro stimulation. In addition, in some experiments, tetanus toxoid (10 μg/ml), phytohaemagglutinin (PHA) 5 μg/ml, and sonicated Mycobacterium tuberculosis (H37Rv; 10 μg/ml) were also employed. To determine IFN-γ production in response to ML, an ELISPOT assay was performed. PBMCs (1 × 105 cells/well) were added in triplicate to a 96-well ELISPOT plate (Millipore, Billerica, MA) coated with anti-human IFN-γ antibody (Gen-Probe, San Diego, CA) and stimulated with ML (10 μg/ml), p38, p69 (10 μg/ml), HIF inhibitor review M. tuberculosis (10 μg/ml), tetanus toxoid (10 μg/ml) and PHA (5 μg/ml) for 48 hr at 37°. The assays were performed according to the manufacturer’s instructions (Gen-Probe, San Diego,

CA). Antigen-specific spot-forming cell frequencies were measured using an automated analyser (CTL Analyzers LLC, Cellular Technology Ltd, Shaker Heights, OH) and expressed per 106 PBMCs. Responses were considered positive if equal or superior to 25 spot-forming cells/106 PBMCs detected after subtracting the background. To characterize the T-lymphocyte subsets involved in the immune response to ML during RR, PBMCs (2 × 106 cells/ml) were suspended in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mm l-glutamine, and 10% fetal calf serum (Gibco BRL, Gaithersburg, MD) and cultured in 24-well

Megestrol Acetate tissue culture plates (Costar, Cambridge, MA) at 37° in 5% CO2 in the presence or not of ML (10 μg/ml) or PHA (5 μg/ml, × 1) for 24 hr. Lymphocytes were collected, harvested with PBS containing 0·1% BSA and 0·01% sodium azide, and blocked for 10 min with PBS containing Fc-receptor blocking solution (BioLegend Inc., San Diego, CA), followed by staining with anti-CD4 [(allophycocyanin), clone RPA-T4, BioLegend Inc.], anti-CD8 (APC, clone SK1, BioLegend Inc.), anti-CD45RA [phycoerythrin (PE), clone MEM-56, Molecular Probes, Eugene, OR], anti-CCR7 (PE-Cy7, clone G043H7, BioLegend Inc.), anti-CD38 (FITC, clone HIT2, Molecular Probes), anti-CD69 (PE, clone CHI4, Molecular Probes) and anti-CD25 (FITC, clone 3C7, BioLegend Inc.) antibodies for 30 min (all 1 : 50 dilution). Cells were subsequently washed twice and fixed with 1% paraformaldehyde.